Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Unilever plc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Unilever plc trades at $62.32 (market cap $134.76B). The key difference: Unilever plc is far larger — about 14.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Unilever plc pays a 3.63% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | UL | |
|---|---|---|
Market Cap | $9.39B | $134.76B |
Sector | Health | Consumer Staples |
52-Week High | $354.54 | $74.59 |
52-Week Low | $241.71 | $55.05 |
Enterprise Value | $9.14B | $160.58B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Unilever (UL) trades at $62.96, down 1.1% over 24 hours, with technical indicators showing a bullish trend and strong support at $62. The company reported $50.5B revenue in 2025 with a net income margin of 18.75%, though recent quarters saw earnings misses. Positive sentiment is driven by a potential merger with McCormick and strong Q2 2026 volume growth, while analyst consensus is mixed with 24% buy ratings.
The outlook is cautiously optimistic due to merger synergies and margin expansion potential, but risks include integration challenges and competitive pressures. Cash flow volatility and debt levels warrant monitoring. The stock presents a value opportunity if execution improves, but near-term volatility may persist amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
